Anergis S.a.

Ecole Polytechnique Federale De Lausanne

Francois Spertini

Blaise Corthesy

Christophe Dominique Reymond

The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.

Allergen peptide fragments and use thereof for treatment of birch pollen allergies

Allergen peptide fragments and use thereof for treatment of dust mite allergies

Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE.

Contiguous overlapping peptides for treatment of ragweed pollen allergy

Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing their ability to bind IgE.

Contiguous overlapping peptides for treatment of birch pollen allergy

Allergen peptide fragments and use thereof

The present invention provides novel protein named Api m 6. Api m 6 was identified in bee venom and is found in four isoforms, each about 8 kD. The purified Api m 6 can be used to modulate immune responses, e.g., in individuals hypersensitive to bee venom.

Growing community of inventors

Epalinges, Switzerland

Francois Spertini